Literature DB >> 19690083

Association between hepatic steatosis and serum IGF1 and IGFBP-3 levels in a population-based sample.

Henry Völzke1, Matthias Nauck, Rainer Rettig, Marcus Dörr, Claire Higham, Georg Brabant, Henri Wallaschofski.   

Abstract

CONTEXT: It is assumed that hepatic steatosis plays a role in the development and progression of the metabolic syndrome and its cardiovascular sequelae. Low serum IGF1 levels might mediate these associations.
OBJECTIVES: The aims of this study were i) to investigate the associations of hepatic steatosis with serum IGF1 and IGF binding protein-3 (IGFBP-3) levels using ultrasound and serum alanine aminotransaminase (ALT) data to define hepatic steatosis, and ii) to analyze the specific role of alcohol consumption in this context.
DESIGN: We analyzed data from the population-based Study of Health in Pomerania.
METHODS: We used data from 3863 subjects (1971 women) aged 20-79 years who had no history of viral hepatitis, liver cirrhosis, or malignant diseases. Liver hyperechogenicity was diagnosed using ultrasound. Serum IGF1 and IGFBP-3 levels were determined by automated two-site chemiluminescence immunoassays.
RESULTS: Hyperechogenic liver pattern was associated with low serum IGF1 levels and low serum IGF1/IGFBP-3 ratios. The lowest serum IGF1 and IGF1/IGFBP-3 values and highest IGFBP-3 levels were present in subjects who had a hyperechogenic liver pattern and increased serum ALT levels. All of these associations were independent of alcohol consumption.
CONCLUSIONS: Our data show that hepatic steatosis is associated with low serum IGF1 levels. This association is independent of alcohol consumption.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19690083     DOI: 10.1530/EJE-09-0374

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  42 in total

1.  Nutrigenomics of hepatic steatosis in a feline model: effect of monosodium glutamate, fructose, and Trans-fat feeding.

Authors:  Kate S Collison; Marya Z Zaidi; Soad M Saleh; Nadine J Makhoul; Angela Inglis; Joey Burrows; Joseph A Araujo; Futwan A Al-Mohanna
Journal:  Genes Nutr       Date:  2011-12-06       Impact factor: 5.523

2.  Vitamin D status may contribute to serum insulin-like growth factor I concentrations in healthy subjects.

Authors:  F Bogazzi; G Rossi; M Lombardi; L Tomisti; C Sardella; L Manetti; O Curzio; C Marcocci; L Grasso; M Gasperi; E Martino
Journal:  J Endocrinol Invest       Date:  2010-07-29       Impact factor: 4.256

3.  Targeted Analysis of Three Hormonal Systems Identifies Molecules Associated with the Presence and Severity of NAFLD.

Authors:  Stergios A Polyzos; Nikolaos Perakakis; Chrysoula Boutari; Jannis Kountouras; Wael Ghaly; Athanasios D Anastasilakis; Asterios Karagiannis; Christos S Mantzoros
Journal:  J Clin Endocrinol Metab       Date:  2020-03-01       Impact factor: 5.958

Review 4.  Multicausality in fatty liver disease: is there a rationale to distinguish between alcoholic and non-alcoholic origin?

Authors:  Henry Völzke
Journal:  World J Gastroenterol       Date:  2012-07-21       Impact factor: 5.742

5.  Relationship between serum circulating insulin-like growth factor-1 and liver fat in the United States.

Authors:  Shauna S Runchey; Edward J Boyko; George N Ioannou; Kristina M Utzschneider
Journal:  J Gastroenterol Hepatol       Date:  2014-03       Impact factor: 4.029

Review 6.  Catalase and nonalcoholic fatty liver disease.

Authors:  Su-Kyung Shin; Hyun-Woo Cho; Seung-Eun Song; Dae-Kyu Song
Journal:  Pflugers Arch       Date:  2018-08-17       Impact factor: 3.657

7.  Relationships between IGF-1 and IGFBP-1 and adiposity in obese African-American and Latino adolescents.

Authors:  Tanya L Alderete; Courtney E Byrd-Williams; Claudia M Toledo-Corral; David V Conti; Marc J Weigensberg; Michael I Goran
Journal:  Obesity (Silver Spring)       Date:  2010-09-30       Impact factor: 5.002

Review 8.  Hepatic steatosis, low-grade chronic inflammation and hormone/growth factor/adipokine imbalance.

Authors:  Giovanni Tarantino; Silvia Savastano; Annamaria Colao
Journal:  World J Gastroenterol       Date:  2010-10-14       Impact factor: 5.742

9.  Hepatic JAK2 protects against atherosclerosis through circulating IGF-1.

Authors:  Tharini Sivasubramaniyam; Stephanie A Schroer; Angela Li; Cynthia T Luk; Sally Yu Shi; Rickvinder Besla; David W Dodington; Adam H Metherel; Alex P Kitson; Jara J Brunt; Joshua Lopes; Kay-Uwe Wagner; Richard P Bazinet; Michelle P Bendeck; Clinton S Robbins; Minna Woo
Journal:  JCI Insight       Date:  2017-07-20

10.  Insulin-like growth factor I, growth hormone, and insulin sensitivity: the effects of a one-year cholecalciferol supplementation in middle-aged overweight and obese subjects.

Authors:  Elena Kamycheva; Vivian Berg; Rolf Jorde
Journal:  Endocrine       Date:  2012-10-30       Impact factor: 3.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.